OM1 launches dataset to expand Parkinson’s evidence in real world
Goal to offer view of course of disease; contribute to research, new treatments
OM1 has launched a Parkinson’s disease premium dataset to expand real-world evidence on the progression of Parkinson’s progression and its treatments.
The goal is to have a comprehensive view of the course of patients’ disease and contribute to accelerating research, assessing therapies’ effectiveness, and supporting procedures to advance new therapies.
“Understanding treatments and disease progression in patients suffering from this devastating illness with real-world data is critical for driving clinical advancements,” Carl Marci, MD, chief psychiatrist and managing director of mental health and neuroscience at OM1, said in a company press release. “Among our goals is to break down barriers that impede access to deep clinical insights that otherwise would go unseen and unused to help develop personalized and targeted treatments for patients with Parkinson’s disease.”
Nearly 1 million people in the U.S. have Parkinson’s, according to the Parkinson’s Foundation, and experts estimate that number could be higher due to people being underdiagnosed or misdiagnosed.
There’s no cure or treatment that significantly reduces the disease’s progression and medications to help control or reduce the symptoms are mostly effective at the disease’s early stages. This means there’s a high unmet need for disease-modifying treatments that can slow down disease progression and deliver more precise care.
What will the Parkinson’s dataset do?
The Parkinson’s dataset can contribute to accelerating medical research and support approvals and reimbursement, potentially reducing the time to market and advance available therapies.
It includes data from more than 7,000 people with Parkinson’s who are followed by neurologists in clinics across all 50 U.S. states. OM1 extracts relevant information from the notes of treating clinicians using its exclusive artificial intelligence and language modeling tools,
The data include information on key symptoms, disease severity, treatments, and clinical response in an evaluation of disease outcomes over time. Deep clinical data are available for more than 4,700 patients, followed by neurologists for a mean of eight years.
The dataset is designed to contribute to gaining more insight into the journey of people with Parkinson’s by combining several real-world data sources such as electronic medical records, medical and pharmacy reimbursement claims, mortality data, and social determinants of health, or, nonmedical factors that affect health outcomes. These include the environmental conditions in which people are born, grow, work, live, and age.
Along with the premium dataset, data from 700,000 other patients are available on the company’s Real-World Data Cloud. This can be used for defining health economics outcomes, patient recruitment for clinical trials, and trends in prescribing medicines, among other research needs. Health economics outcomes identify what, how, and to whom appropriate healthcare should be provided, considering the cost-effectiveness ratio.
The Parkinson’s premium dataset is part of the company’s Mental Health & Neuroscience data network, which involves more than 9,000 specialty doctors and more than 2,500 specialty practices. It includes data on other conditions, such as depression, bipolar disorders, schizophrenia, and multiple sclerosis. In the coming months, it will be expanded to add data from people with Alzheimer’s disease, another neurodegenerative disease.
About the Author
